36 results on '"Shepherd, Frances A."'
Search Results
2. Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
3. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer
4. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre
5. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis
6. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)
7. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors
8. Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data
9. Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System
10. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer
11. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer
12. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
13. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy
14. Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade
15. ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
16. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer
17. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model
18. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer
19. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24
20. Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma
21. A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium
22. Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma
23. Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy
24. Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial
25. Treatment patterns and outcomes of patients with advanced pleural mesothelioma at an academic referral centre
26. Understanding Prognostic Gene Expression Signatures in Lung Cancer
27. Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?
28. Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non–Small-Cell Lung Cancer
29. K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review
30. Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21
31. Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data.
32. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
33. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations
34. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations
35. A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (CaelyxTM) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer
36. K-rasMutations in Non-Small-Cell Lung Carcinoma: A Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.